223 results on '"Cheema, Parneet"'
Search Results
2. Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
3. Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC
4. Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies
5. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial
6. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada
7. Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer.
8. Point of Care Liquid Biopsy for Cancer Treatment—Early Experience from a Community Center.
9. Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
10. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer
11. Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendations.
12. The Perceived Value of Avoiding Tissue Biopsy: Results from a Canadian Validation Study of Circulating Tumour DNA T790M Testing – Patient’s Willingness to Pay: A Brief Report
13. 695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)
14. Treatment patterns and outcomes in KRASG12C‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study
15. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study
16. Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs: a systematic review and meta-analysis
17. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
18. Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib
19. The Perceived Value of Liquid Biopsy: Results From a Canadian Validation Study of Circulating Tumor DNA T790M Testing—Patient’s Willingness-to-Pay: A Brief Report
20. Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer
21. Abstract CT229: CRESTONE: A Phase 2 study of seribantumab in adult patients with neuregulin-1 (NRG1) fusion positive locally advanced or metastatic solid tumors
22. Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary
23. Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices
24. A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data
25. Fast Facts: Molecular Profiling in Solid Tumors
26. Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer
27. A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib
28. Fast Facts: EGFR Exon 20 Mutations in Non-Small-Cell Lung Cancer
29. CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions.
30. Mitigating the risk of COVID-19 in a large community oncology clinic and its impact on the patient experience.
31. Randomized phase 2 study evaluating efficacy and safety of inupadenant in combination with chemotherapy in adults with metastatic non–small cell lung cancer (mNSCLC) who progressed on immunotherapy.
32. Rapid access to biomarker data in a community setting: Integration of next-generation sequencing into routine pathologic workflow.
33. PPD01.02 Repotrectinib in Patients With ROS1Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 Trial
34. Intracranial Metastatic Disease: Present Challenges, Future Opportunities
35. Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care
36. A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre
37. Rapid point of care NGS in colorectal cancer.
38. Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional Experience
39. Konsensusempfehlungen zur Optimierung von Tests auf neue geeignete Zielmutationen bei nicht kleinzelligem Lungenkrebs
40. Egfr Mutation Prevalence, Real-World Treatment Patterns, and Outcomes Among Patients with Resected, Early-Stage, Non-Small Cell Lung Cancer in Canada
41. The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer
42. Canadian Consensus Recommendations on the Management of MET-Altered NSCLC
43. Age 40 Years and Under Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transmplant
44. sj-docx-1-tam-10.1177_17588359211056306 ��� Supplemental material for The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
45. Clinicogenomic real-world data analysis of patients (pts) with KRAS G12C-mutant advanced non-small cell lung cancer (aNSCLC) from the natural history cohort of the Blood First Assay Screening Trial (BFAST).
46. Sequencing of systemic therapies in advanced NSCLC with MET exon 14 skipping mutation: A multicenter experience.
47. A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable Non-Small Cell Lung Cancer
48. The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
49. A reply to “Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model”
50. Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.